Business Context and Reporting Period
This Form 8-K filing by InMed Pharmaceuticals Inc. (INM) covers the event date of March 19, 2024. The Company, incorporated in British Columbia and listed on the Nasdaq Capital Market, is an emerging growth company. The report addresses a regulatory matter concerning the continued listing of its common shares.
Key Financial Metrics
This filing is a current report regarding a listing status update and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the extension of the compliance period regarding Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Rule). Previously notified on September 19, 2023, that its shares failed to meet the $1.00 minimum bid price requirement, the Company was initially granted 180 days to regain compliance. On March 19, 2024, Nasdaq granted an additional 180-day compliance period, extending the deadline to September 16, 2024.
Outlook, Risks, and Management Commentary
- Compliance Path: To regain compliance, the Company must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days prior to September 16, 2024.
- Strategic Options: Management has notified Nasdaq of its intention to consider all available options to regain compliance, including, if necessary, effecting a reverse stock split.
- Delisting Risk: If the Company fails to regain compliance by the end of the Extended Compliance Period, Nasdaq will notify the Company that its shares will be delisted.
- Appeal Process: In the event of a delisting determination, the Company may appeal to a Hearings Panel, though there is no assurance of success.
- Trading Status: The notification has no immediate effect on trading; shares will continue to trade on the Nasdaq Capital Market under the symbol "INM."
Investor Verification Checklist
- Verify the current closing bid price of INM shares to assess proximity to the $1.00 threshold.
- Monitor for any press releases or filings regarding a proposed reverse stock split.
- Track the 10 consecutive business days of $1.00+ closing prices required to close the compliance matter early.
- Review the Company's cash position in other filings to determine its ability to fund operations if a reverse split is not executed or if delisting occurs.